Sanara MedTech
SMTI | NASDAQ
$32.76
+$0.41 (+1.27%)
At close: Nov 16, 2026, 4:00 PM ET
$32.76
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:15 PM ET
Sanara MedTech Company Profile
Company profile explainedCompany Profile
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Key Executives
| Name | Position |
|---|---|
| Seth Yon | President, Chief Executive Officer & Director |
| Suresh V. Muppalla | President & Chief Executive Officer of THP |
| Elizabeth Taylor | Chief Financial Officer |
| Jacob A. Waldrop | Chief Operating Officer |
| Ashley Mackey | Principal Accounting Officer |
| Bill Fitzgerald | Chief Compliance Officer |
| Nicholas Gachassin | General Counsel |
| Nina Bionda | Chief R&D Officer |
| Ronald T. Nixon | Executive Chairman |
| Tricia Matteson | Vice President of Marketing |
| Tyler Palmer | Chief Corporate Development & Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 28, 2026 | 425 | Filing |
| Oct 16, 2026 | 425 | Filing |
| Oct 16, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 425 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 04, 2026 | DEFM14A | Filing |
| Aug 20, 2026 | 425 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
Sanara MedTech
| Country | United States |
| IPO Date | Apr 7, 1994 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Seth D. Yon |
Contact Details
1200 Summit Avenue Fort Worth,
Texas 76102 United States
Stock Details
| Ticker Symbol | SMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000714256 |
| CUSIP Number | 79957L100 |
| ISIN Number | US79957L1008 |
| SIC Code | 3842 |
Add to Watchlist
Select watchlists to add or remove SMTI